Vector BioMed launches with $15M to produce backlogged CAR-T component
The manufacture of lentiviral vectors has been grabbing the attention of investors both small and large as of late, and another manufacturer is looking to jump onto the scene.
Vector BioMed, a Maryland-based biomanufacturing company, has raised $15 million, according to CEO Boro Dropulić in an interview with Endpoints News. The impetus behind the company, Dropulić said, is for Vector BioMed to fill a gap in the demand and access to lentiviral vectors, a key component in CAR-T therapies and other treatments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.